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Genomic disruption of the histone methyltransferase SETD2
in chronic lymphocytic leukaemia
H Parker1,15, MJJ Rose-Zerilli1,15, M Larrayoz1,15, R Clifford2, J Edelmann3, S Blakemore1, J Gibson4, J Wang5, V Ljungström6, TK Wojdacz1,
T Chaplin5, A Roghanian1, Z Davis7, A Parker7, E Tausch3, S Ntoufa8, S Ramos2, P Robbe2, R Alsolami2, AJ Steele1, G Packham1,
AE Rodríguez-Vicente9, L Brown1, F McNicholl10, F Forconi1, A Pettitt11, P Hillmen12, M Dyer13, MS Cragg1, C Chelala5, CC Oakes14,
R Rosenquist6, K Stamatopoulos8, S Stilgenbauer3, S Knight2, A Schuh2, DG Oscier1,7 and JC Strefford1
Histone methyltransferases (HMTs) are important epigenetic regulators of gene transcription and are disrupted at the genomic
level in a spectrum of human tumours including haematological malignancies. Using high-resolution single nucleotide
polymorphism (SNP) arrays, we identiﬁed recurrent deletions of the SETD2 locus in 3% (8/261) of chronic lymphocytic leukaemia
(CLL) patients. Further validation in two independent cohorts showed that SETD2 deletions were associated with loss of TP53,
genomic complexity and chromothripsis. With next-generation sequencing we detected mutations of SETD2 in an additional 3.8%
of patients (23/602). In most cases, SETD2 deletions or mutations were often observed as a clonal event and always as a mono-allelic
lesion, leading to reduced mRNA expression in SETD2-disrupted cases. Patients with SETD2 abnormalities and wild-type TP53 and
ATM from ﬁve clinical trials employing chemotherapy or chemo-immunotherapy had reduced progression-free and overall survival
compared with cases wild type for all three genes. Consistent with its postulated role as a tumour suppressor, our data highlight
SETD2 aberration as a recurrent, early loss-of-function event in CLL pathobiology linked to aggressive disease.
Leukemia (2016) 30, 2179–2186; doi:10.1038/leu.2016.134
INTRODUCTION
The transfer of methyl groups from S-adenosyl methionine
to lysine or arginine residues on histone proteins, catalysed
by histone methyltransferases (HMTs), is an important regulator of
gene transcription. Accordingly, HMTs are disrupted by various
mechanisms, including chromosomal translocations, genomic
loss and/or point mutations in both solid and haematological
malignancies.1 Among the increasing number of HMT aberrations
identiﬁed in human malignancies, recurrent loss and/or inactivat-
ing mutations of the tumour suppressor gene SETD2 were initially
identiﬁed in clear cell renal cell carcinoma2 and subsequently in
other solid tumours, for example, high-grade gliomas.3 Moreover,
SETD2 mutations have been reported in a subset of patients with
acute lymphoblastic leukaemia4 and acute myeloid leukaemia,
especially those with rearrangements in the another HMT gene,
MLL.5 SETD2 is the only enzyme that catalyses the trimethylation
of lysine 36 on histone 3 (H3K36me3), one of the major chromatin
marks associated with active transcription. Recent studies have
linked SETD2 to the maintenance of genomic integrity through
coordination of homologous recombination repair after double
strand breaks. The loss of SETD2 impairs DNA repair and enhances
genomic instability, supporting its tumour suppressor role.6–9
Chronic lymphocytic leukaemia (CLL) is characterized by remark-
able clinical heterogeneity such that some patients pursue an
indolent course while others require early treatment. Considerable
effort has focused on understanding the genetic diversity that
underpins this clinical heterogeneity. High-resolution genomic arrays
and next-generation sequencing have identiﬁed recurring novel
regions of genomic copy-number aberrations (CNAs) like del(13q),
del(11q), trisomy 12 and del(17p) and recurrent driver mutations in
genes such as TP53, ATM, SF3B1 and NOTCH1, respectively (reviewed
in Guièze and Wu10). Mutations frequently involve genes encoding
proteins with important roles in cell signalling, cell cycle control, DNA
repair and RNA splicing and processing; however the reported
incidence of mutations in chromatin modiﬁers is lower than in many
other haematological malignancies.
In this study, we report the identiﬁcation of recurrent deletions
and mutations of the SETD2 gene in large, well-characterized
CLL cohorts. SETD2 lesions appear to represent early events in
CLL pathogenesis, often coexisting with, but preceding TP53
abnormalities. They are associated with genomic complexity and
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chromothripsis, and identify a subgroup of patients with poor
outcome.
PATIENTS AND METHODS
Patients
We studied samples taken from 1006 CLL patients either at entry into one of
ﬁve clinical trials or from a cohort of untreated patients with progressive
disease managed at the Royal Bournemouth Hospital. Four randomized trials
(ADMIRE, ARCTIC, UK CLL4(ref. 11) and GCSG CLL8(ref. 12)) compared chemo or
chemo-immunotherapy regimens in ﬁt previously untreated patients while
the ﬁfth trial (SCSG CLL2O) enroled ultra-high-risk patients who were either
refractory to a purine analogue or were previously untreated with a 17p
deletion. Further details of the clinical trials are provided in Supplementary
Table S1. All patients were diagnosed using standard morphologic and
immunophenotypic criteria. Informed consent was obtained from all patients
in accordance with the Helsinki declaration, and this study was approved by
national or regional research ethics committees.
Patients were grouped into three cohorts (discovery (n=261), extension
(n=635) and ultra-high-risk (n=110)); details of the cohort composition
and SETD2 analysis are summarized in Table 1, Supplementary Methods and
Supplementary Figure S1. DNA was extracted from CLL B-cell samples (all with
480% tumour purity) and from matched germline DNA for SETD2-mutated
cases as outlined in Supplementary Methods. The assessment of established
biomarkers was performed as previously described.13 In total, 572 and 602
samples were screened for SETD2 loss and mutation, respectively, with 168
cases screened for both loss and mutation.
Genome-wide microarray-based copy-number analysis
DNA from 261 discovery and 110 ultra-high-risk cases was ampliﬁed, labelled
and hybridized to the Affymetrix SNP6.0 platform, aligned onto the human
genome sequence (GRCh37) and analysed in Partek Genomics Suite (Partek,
St Louis, Inc., MO, USA) as reported previously.14–18 DNA from 201 pre-
treatment extension cases (ADMIRE and ARCTIC) was hybridized to the
Illumina HumanOmni1-Quad and HumanOmniS-8 platforms according to
the manufacturer’s protocols.19,20 Further experimental details are provided in
the Supplementary Methods.
Targeted re-sequencing and whole-exome sequencing
Ninety-three CLL samples from the discovery cohort (and ﬁve matched
germline controls) were processed and analysed for mutations in SETD2 (all
exons) and a number of clinically relevant genes with a bespoke Haloplex
Target Enrichment system (Agilent Technologies, Santa Clara, CA, USA)
(Supplementary Methods and Table 1) and processed and analysed as
previously reported.21 An additional 231 cases from our pre-treatment
extension cohort were screened for SETD2 mutations using a TruSeq Custom
Amplicon panel (Illumina Inc., San Diego, CA, USA) as previously
described.20,22 All the variants identiﬁed by both platforms were annotated
against dbSNP (build 135) and functional prediction was also performed using
SIFT andPolyphen2 analysis. Somatically acquired SETD2 mutations (n=4)
were also identiﬁed in the recent whole-exome sequencing study of 278
matched tumour and germline cases from the GCSG CLL8 study.23 Additional
experimental details are provided in the Supplementary Methods.
Sanger validation
Variants in SETD2 were subjected to validation by conventional Sanger-based
sequencing of PCR products obtained from tumour (n=11) and where
possible, paired normal genomic DNA (n=5). The expression of SETD2
mutations at mRNA level was also tested in samples with available material
(n=4). Primers for DNA or mRNA validation are listed in Supplementary
Table S2.
Quantitative reverse transcriptase-PCR
Total RNA was isolated from puriﬁed CLL cells of 36 patient samples using
RNeasy columns (Qiagen, Manchester, UK) and reversed transcribed using the
Improm II RT-PCR kit (Promega, Southampton, UK) according to the
manufacturer’s instruction. Primers and probes for the housekeeping genes
(18 s) and target genes (CCDC12, NBEAL2, KIF9, KLHL18, SETD2) were selected
using the Universal Probe Library (Roche Applied Science, Burgess Hill, UK)
(Supplementary Table S3). Two independent assays were designed to ascertain
expression of 3′ and 5′ SETD2. Normal B-cell mRNA was use to normalize the
expression of each gene by delta-delta CT method as previously described.24
Statistical analysis
Statistical analysis was performed with SPSS v22. Differences between
samples were analysed by Mann–Whitney U-test. Progression-free survival
(PFS) and overall survival (OS) were calculated for clinical trial samples from
randomization. Survival analysis was performed by Kaplan–Meier and log-
rank analysis. Signiﬁcant differences were considered with P-values lower
than 0.05.
RESULTS
Recurrent deletions of 3p are a feature of CLL
We identiﬁed 1024 acquired CNAs (mean 3.9, range 0–45) in our
discovery cohort (Supplementary Table S4). Deletions of chromo-
some 3p [del(3p)] were observed in eight patients (3%), ranged
from 0.45 to 81 Mb in size (Supplementary Table S5) and identiﬁed
a well delineated minimally deleted region (MDR) between
genomic location 46.96 and 47.39 Mb, containing the genes
CCDC12, NBEAL2, SETD2, KIF9 and KLHL18 (Figure 1a). We
Table 1. Cohort characteristics
Characteristics Discovery,
N (%)
Extension,
N (%)
Ultra-high-
risk, N (%)
Number of cases (number
with germline material)
261 (5) 635 (280) 110
Origin CLL4/Local
cohort
CLL4/ARCTIC/
ADMIRE/CLL8
CLL2O
Treatment naïve
Yes 261 (100) 635 (100) 35 (32)
No — — 75 (68)
Gender
Male 192 (74) 336 (53) 79 (72)
Female 69 (26) 299 (47) 31 (28)
IGHV gene mutational status
Unmutated 120 (46) 350 (55) 96 (87)
Mutated 68 (26) 232 (37) 12 (11)
No data 73 (28) 53 (8) 2 (2)
del(17p)
Yes 29 (11) 32 (5) 88 (80)
No 214 (82) 565 (89) 22 (20)
No data 18 (7) 38 (6) —
del(11q)
Yes 79 (30) 138 (22) 21 (19)
No 165 (63) 461 (73) 89 (81)
No data 17 (7) 36 (5) —
Tri12
Yes 23 (9) 58 (9) 19 (17)
No 199 (76) 418 (66) 91 (83)
No data 39 (15) 159 (25) —
Del(13q)
Yes 103 (40) 252 (40) 65 (59)
No 63 (24) 224 (35) 45 (41)
No data 95 (37) 159 (25) —
Chromothripsis 8 (3) 9 (1.4) 10 (9)
SETD2 deleted 8/261 (3) 9/201 (4.5) 10/110 (9)
SETD2 mutated 4/93 (4.3) 11/509 (2.2) —
SETD2 deleted with
TP53 abnormalities
3/8 (37.5) 5/9 (55.5) 10/10
(100)
SETD2 mutated with
TP53 abnormalities
0/4 (0) 4/11 (36.4) —
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compared the expression of these genes by quantitative reverse
transcriptase-PCR in 3p deleted (n= 6) versus non-3p deleted
patients (n= 8) (Figure 1c). We were not able to detect the
expression of KIF9 mRNA in CLL or normal B-cells. Within the MDR,
the HMT gene SETD2 was signiﬁcantly underexpressed, measuring
by two different assays targeting the 3′ or 5′ region of the mRNA
(Po0.0001 for both assays).
We then aimed to conﬁrm the presence of 3p deletions and
reﬁne the MDR in our extension cohorts. Firstly, we identiﬁed
nine del(3p) cases (4.5%) in our extension pre-treatment cohort,
permitting the MDR to be reﬁned to the SETD2 and KIF9
loci (47.12–47.36 Mb; Figure 1a and Supplementary Table S5).
Across our discovery and pre-treatment extension cohorts,
SETD2 deletions were present in 17/461 cases (3.7%), signiﬁcantly
associated with deletions and/or mutations of TP53 (P= 0.003) and
genomic complexity (⩾3 deletions,25 P= 0.04) (Figure 1b). GISTIC
2.0 analysis,26 an algorithm for identifying statistically signiﬁcant
regions of CNA above an estimated background rate (FDR q-value
o0.25), showed that in 39 TP53 deleted cases (del(3p), n = 15),
the SETD2 region on 3p21.31 was deleted at a signiﬁcant
frequency (q-value = 0.001), ranked third after del(13q) and del
(17p) (Supplementary Figure S2).
Interestingly, SETD2 deletions without concomitant TP53/ATM
abnormalities (n= 6) also exhibited signiﬁcantly more genomic
complexity than wild-type patients (P= 0.01; Figure 1d). Two
SETD2-deleted cases showed evidence of chromosome 3 chromo-
thripsis (based on 410 CNAs per chromosome18) (Figures 1a
and b). In the ultra-high-risk cohort, SETD2 deletions were
detected in 9% of cases (10/110), and were signiﬁcantly enriched
compared with the pre-treatment cohort (P= 0.009). All 10 had
loss of TP53 and 5 had concomitant chromosome 3 chromo-
thripsis (Figure 1b). To further establish the signiﬁcance of our
SETD2 deletion in cases with chromosome 3 chromothripsis, we
mapped all recurrently 3p deletions in these cases. This analysis
Figure 1. SETD2 deletions in our discovery, extension and ultra-high-risk cohorts. (a) SNP6.0 data for the del(3p) cases. Genomic location is
indicated by the ladder to the left. Each column represents one patient. Loss, gain and normal copy number are shown as blue, red and white,
respectively. The black box indicates the MDR, and is displayed in greater detail for our discovery and extension cohorts. The genes in the
MDR with their transcriptional direction are displayed in the middle, with the MDR from the discovery and extension cohorts shown by the
red and purple bars, respectively. (b) Matrix displaying the biomarkers and genomic features associated with del(3p) cases with the discovery,
extension and ultra-high-risk cases shown in red, purple and yellow, respectively. (c) Real-time PCR expression for the ﬁve genes localized in
the discovery MDR in cases with or without del(3p). All the samples were negative for KIF9. 18 s was employed as housekeeping gene.
Expression in normal B-cells was used as a normalization sample. Mean± s.d. is represented. (d) Scatterplots displaying the number of CNA
observed in subgroups of our cohort (excluding ultra-high-risk cases). Cases were assigned to a subgroup using a hierarchical model; presence
of del(17p) and/or TP53 mutation, then del(11q) and/or ATM mutation, then del(3p) cases with and without TP53 abnormalities and then
wild-type (WT) cases containing no del(17p), del(11q), del(3p) or mutations in ATM and TP53. Mean± s.d. is represented.
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showed that while additional regions of recurrent deletion were
observed on 3p, the only regions shared across all patients
included the SETD2 locus (Supplementary Table S6).
We analysed SETD2 expression in an extended cohort of patients
with 3p deletions (n=16), and again the expression was diminished
in these patients compared with wild-type patients (P=0.0068;
Supplementary Figure S3). In order to study the clonal nature of the
SETD2 deletions, we assigned each genomic CNA with a relative
copy-number value by normalizing CNA intensity values from
array features. We excluded regions with gain and sex chromosome
CNAs from the analysis. The cutoff for normal copy number was
established between 1.7 and 2.3. We could infer that the 3p deletion
was in the dominant clonal population in 11/18 (61%) cases with
data available for analysis (Supplementary Figure S4).
SETD2 mutations in CLL
To identify somatic gene mutations, we initially employed targeted
re-sequencing of 93 discovery cohort cases and identiﬁed 122 non-
silent mutations (non-synonymous n=80, frameshift indel n=20,
splicing n=9, nonframeshift indel n=6, stopgain n=6, stoploss
n=1) targeting 37 genes in 71/93 cases (mean 1.8, range 1–4).
Sanger sequencing conﬁrmed 93.6% of the tested variants (n=79),
while the remaining unconﬁrmed variants were present at low read
depth (n=3) or in a low percentage of mutant reads (n=2). We
found ATM (n=14), TP53 (n=14), NOTCH1 (n=20) and SF3B1 (n=15)
mutations at a frequency expected for the studied cohort, which
aligns with published data and demonstrates the validity of the
re-sequencing platform. We identiﬁed non-synonymous SETD2
mutations in four (4.3%) discovery cases (p.D99G, p.Q1545K,
p.W1306*, p.E1955Q) (Figures 2a and b). Sanger sequencing
validated that all of the SETD2 mutations were present in tumour
DNA. We obtained matched germline DNA from three patients and
conﬁrmed that the mutations were somatically acquired (p.D99G,
p.W1306*, p.E1955Q) (Supplementary Figure S5A).
To corroborate this preliminary observation, we investigated 231
cases of our pre-treatment extension cohort by TruSeq amplicon-
based sequencing. We identiﬁed an additional nine (3.9%) SETD2
mutations (p.A50T, p.L89F, p.P167L, p.N535S, p.E670K, p.M1742L,
p.M1889T (x2), p.I2295M) (Figures 2a and b). Sanger sequencing
conﬁrmed each SETD2 variant in the tumour material and in two
cases with germline material available, the variants were somatically
acquired. Assessment of whole-exome sequencing data of the
CLL8 study23 samples included in our pre-treatment extension
cohort revealed the presence of somatically acquired SETD2
mutations in 4/278 cases (1.4%), namely, p.EEEELQSQQ1919fs,
p.L1804fs, p.VLEYC1576del, p.V1190M. None of these SETD2 muta-
tions (Table 2) are annotated in COSMIC.27 During the preparation of
this manuscript, a study performed by Puente et al.28 in 506 CLL
patients also described both SETD2 mutations (0.8% of cases) and
deletions in 3p (2% of cases) whose MDR encompassed SETD2 while
Landau et al.23 identiﬁed SETD2 mutations in 8/538 (1.5%) cases.
In total, across our cohorts there were 15 somatically acquired
SETD2 variants (15/602; 2.5%). An additional eight variants that
could not be examined in germline material were either absent
(n= 3), reported to have a very low prevalence (n= 5) in 1000
Genomes project or have a subclonal variant allele frequency
(%VAF o0.45 (n= 1); Table 2). Therefore, while these eight
variants are predicted to be functionally deleterious, we cannot
exclude that the minority may be rare germline variants as they
exhibit clonal variant allele frequencies in the tumour material.
We were able to conﬁrm the expression of the SETD2
mutations at mRNA level in four of our patients with available
material (p.D99G, p.Q1545K, p.E1955Q, p.E670K) (Supplementary
Figure S5A), and quantiative reverse transcriptase-PCR analysis
of three SETD2 mutated samples showed that SETD2 mRNA
expression was reduced compared with wild-type patients
(P = 0.035; Supplementary Figure S3).
We performed integrative analysis of 93 cases from our
discovery cohort with Haloplex re-sequencing and SNP6.0
copy-number data available, by employing the ABSOLUTE
algorithm.29 This approach estimates the cancer cell fraction
harbouring a given mutation by correcting for sample purity and
local copy-number changes. Mutations were classiﬁed as clonal if
the cancer cell fraction was 40.95 with a probability 40.5 and
subclonal otherwise.30 In additional cases with proven-somatic
SETD2 mutations (n= 4) and paired copy-number data from our
pre-treatment validation cohorts, we performed this estimation by
manually correcting for tumour sample purity and local copy
number. Our analysis demonstrated the expected subclonal
distribution of established gene mutations, such as TP53, ATM,
SF3B1 and NOTCH1. Interestingly, all our somatically acquired
SETD2 mutations exhibited a clonal cancer cell fraction, suggesting
that these mutations may be early events in the evolution of CLL
(Figures 2c and d and Supplementary Figures S5B and C),
although further studies are required to conﬁrm this observation.
SETD2 aberrations are associated with inferior progression-free
and OS
Finally, we analysed the impact of SETD2 abnormalities (deletion
or somatically acquired mutation) on PFS and OS in front-line
trial patients. We observed a signiﬁcantly shorter PFS in cases with
SETD2 abnormalities that were wild type for TP53/ATM (n= 7),
compared with cases wild type for TP53/ATM/SETD2 (n= 62) (PFS:
30 vs 48 months; P= 0.003) (Figure 2e). The same patients with
SETD2 abnormalities (n= 7) also had a shorter OS than wild-type
patients (n= 62) (OS: 34 vs 92 months; Po0.001) (Figure 2f). While
these data suggest that SETD2 aberration may be clinically
relevant, further investigation in larger cohorts is needed to
understand their full impact on survival.
DISCUSSION
This study was based on an initial high-resolution SNP6.0 array
analysis of 261 untreated patients with progressive CLL, which
identiﬁed a recurrent deletion of the short arm of chromosome 3
in 3% of cases (n= 8). The MDR included the CCDC12, NBEAL2,
SETD2, KIF9 and KLHL18 genes, of which SETD2 was the most
signiﬁcantly underexpressed in tumour cells. We then identiﬁed
clonal, somatically acquired SETD2 mutations in 4.3% of this
cohort; no mutated case had a concomitant SETD2 deletion.
The SETD2 gene encodes a 230 kDa protein that is non-redundantly
responsible for all trimethylation of lysine 36 on histone H3
(H3K36me3),31,32 a mark that is associated with actively tran-
scribed regions and is involved in transcriptional elongation and
splicing.33 In addition, recent studies have linked this epigenetic
histone mark to other important cellular processes such as the
regulation of mismatch repair, efﬁcient homologous recombination
and the maintenance of genomic stability.7–9 In vitro inhibition of
Setd2 decreases global levels of H3K36me3 and impairs the
recruitment of the mismatch recognition protein hMutSα onto
chromatin, thereby preventing appropriate DNA mismatch repair.
Cells lacking the Setd2 protein display microsatellite instability
and have elevated levels of spontaneous mutations.7,34–36 Inactivat-
ing SETD2 mutations were ﬁrst described in clear cell renal cell
carcinoma,2,6 subsequently in other solid tumours such as paediatric
high-grade gliomas and most recently in a subset of patients
with acute lymphoid and myeloid leukaemias.2,5,37,38 SETD2 muta-
tions in clear cell renal cell carcinoma are frequently associated
with 3p deletions resulting in loss of both SETD2 and VHL genes,
while in acute leukaemias, SETD2 mutations may be bi-allelic but
3p loss is rare. SETD2 genomic abnormalities are associated
with decreased H3K36me3 levels, a distinctive DNA methylation
signature6 and chemoresistance in paediatric acute lymphoblastic
leukaemia.39 In MLL-rearranged cells from acute leukaemic patients,
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Figure 2. SETD2 mutations in our discovery and extension cohorts. (a) Schematic diagram of the Setd2 protein with their key functional
domains. Mutations are displayed in the diagram. The colour denotes the cohort, and the ﬁlled circles are mutations that have been
conﬁrmed as somatically acquired. (b) Matrix displaying the biomarkers and genomic features associated with SETD2-mutated cases in the
discovery (red) and extension (purple) cases. (c) Analysis of the clonality for SETD2 and other recurrently mutated genes on CLL. For each case
the cancer cell fraction (CCF) is derived manually or with the ABSOLUTE algorithm. Only somatically acquired validated mutations are
displayed (cases 69, 100, S21 and 88). The number of mutations (n) for each gene in the analysis is shown (bottom). (d) Percentage of cases
harbouring clonal or subclonal mutations for each of the genes displayed. (e) Kaplan–Meier and log-rank analysis for progression-free survival
(PFS) in patients carrying SETD2 abnormalities (‘SETD2 ab’) but wild type for TP53 or ATM deletion and/or mutation compared with those with
TP53 abnormalities (‘TP53 ab’) and those wild type for TP53, ATM and SETD2 (‘wild type’). (f) Kaplan–Meier and log-rank analysis for overall
survival (OS) in the same categories described in (e).
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Setd2 knockdown is implicated in disease initiation and progression
by promoting the self-renewal capacity of leukaemic stem cells.
In view of the role of SETD2 disruption in tumorigenesis and
the identiﬁcation of SETD2 abnormalities in our discovery cohort,
we then accrued samples from other patient cohorts, including
the GCLLSG CLL8 cohort in which 3p deletions had also been
detected,18 to conﬁrm the incidence of SETD2 disruption and
evaluate its biological and clinical consequences in CLL. Previously
untreated patients sampled at randomization to chemo or chemo-
immunotherapy trials had a similar incidence of 3p deletions
(4.5%) to that seen in the discovery cohort while a higher
incidence of loss (9%) was found in the ultra-high-risk cohort.
The inclusion of additional cohorts enabled a smaller MDR to
be deﬁned, including SETD2 and KIF9, implicating SETD2 as the key
deleted gene. The incidence of SETD2 mutations was comparable
in all cohorts tested, no synonymous mutations were identiﬁed
and when germline material was tested, all mutations were
somatically acquired. The diverse sequencing strategies utilized
in this current study precluded the application of computational
tools like MutSigCV,40 an algorithm that identiﬁes signiﬁcantly
mutated genes by accounting for background mutation rate, DNA
replication time and the gene size. However, we did assess the
SETD2 background mutation rate, expression level and replication
timing data from Lawrence et al.40 demonstrating that SETD2
shares no properties associated with false-positive candidate
cancer genes (Supplementary Figure S7). The recent studies by
Puente et al. and Landau et al. published during the preparation of
this manuscript conﬁrm the rare but recurrent nature of SETD2
abnormalities.23,28 SETD2 deletions were not over-represented by
analysis of whole-exome sequencing generated copy-number
data in the work by Landau and the mutation frequencies of
both studies were lower than those in our study. The different
frequencies reported in these two studies could be explained
by cohort composition, as our study included ultra-high-risk CLL
and patients randomized to clinical trials.
As we found SETD2 mRNA expression to be downregulated
in cases with either SETD2 deletion or mutations and as we did
not observe bi-allelic SETD2 abnormalities, we assessed whether
SETD2 may also be deregulated by DNA methylation. Kulis and
co-workers41 reported no differential methylation levels in the
SETD2 gene body and promoter regions (15 and 9 CpG probes),
respectively, between unmutated or mutated CLL or major
cytogenetic subtypes and SETD2 mRNA expression was not
correlated with gene methylation status (doi:10.1038/ng.2443:
Supplementary Tables S5 and S11).41 Preliminary analysis of our
own unpublished Illumina 450 K methylation array data also
demonstrated no differences between mutated and unmutated
CLL for these probes (Supplementary Figure S6). In addition,
when we analysed SETD2 expression in a published CLL data set
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc =GSE2466)44
using the Oncomine portal (https://www.oncomine.org),42 we
observed a heterogeneous pattern. Reduced levels are evident
in the minority of patients, which given our observed association
between SETD2 deletion and expression could imply gene
deletion in those Oncomine samples with low mRNA expression.
Together, this suggests that DNA methylation does not play a
substantial role in regulating SETD2 expression in B-CLL cells, as
previously noted in acute leukaemia.5
Across all cohorts, SETD2 deletion was found in both IGHVmutated
and unmutated cases but was strongly associated with TP53 loss and
mutation, likely accounting for its higher incidence in the ultra-high-
risk cohort. We also noted an association with genomic complexity
even in cases lacking a TP53 or ATM abnormality, consistent with
the role of SETD2 in maintaining genomic stability. Moreover, we
identify several SETD2 deletions that appeared to be the result of
chromothripsis. The somatically acquired SETD2 mutations showed
a comparable genomic distribution to those previously described in
other tumours and were predicted to have deleterious functional
consequences. Furthermore, their association with signiﬁcantly
reduced mRNA expression in those cases analysed, suggest that
they either directly affect mRNA expression or coexist with other
defects in transcriptional control at this locus. Interestingly, we
did not observe a statistically signiﬁcant association between SETD2
mutations and TP53 abnormalities or genomic complexity, the
implication of which may be differing functional consequences of
mono-allelic loss and mutation.
In our study, both SETD2 deletions and mutations often
appeared to be clonal and may precede TP53 abnormalities
in at least some cases. Setd2 has been shown to directly regulate
the transcription of a subset of genes via cooperation with the
transcription factor p53,43 and the link between SETD2 and TP53
is an interesting association worthy of functional validation. It is
possible that the SETD2 alterations present in our CLL cases may
contribute to further inactivation of p53-mediated checkpoint
control, a situation that has been proposed in clear cell renal cell
carcinoma.8 The low frequency of SETD2 disruption and the
association with TP53 abnormalities hinder an accurate assess-
ment of its clinical consequences. Nevertheless, we observed
a shorter PFS and OS in patients with SETD2 but no TP53 or ATM
abnormalities compared with cases wild type for all three genes.
In support of this preliminary clinical observation, it has been
shown that 3p deletions in head and neck squamous carcinoma
are associated with reduced survival.44 Furthermore, the authors
showed that the coexistence of a TP53 abnormality with del(3p)
decreased survival further, an observation that we could not
conﬁrm in our cohort.
In summary, our current study provides the ﬁrst comprehensive
analysis of CNAs and mutations targeting the SETD2 gene in a
large cohort of patients with CLL. We ﬁnd somatic deletions and
mutations in ~7% of CLL patients requiring treatment. These
associate with TP53 dysfunction, genomic complexity and chromo-
thripsis and may be early clonal events. Functional studies are now
warranted to elucidate the exact biological importance of SETD2 in
CLL pathogenesis, but our data add to a growing body of evidence
suggesting a role for H3K36me3 in tumorigenesis that may
be exploited for the development of novel therapeutic approaches.
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